Better Health for All

MiMedx's core products, EPIFIX and EPICORD, demonstrate substantial health benefits, with clinical trials showing high wound closure rates (e.g., 92% at 6 weeks) and significant wound size reduction (93.9% vs. -10.6% for standard of care).

The company received a $4.6 million award from the Department of Defense in May 2022 to evaluate placental tissue for wound and burn care, including preventing partial-thickness burns from deteriorating. However, the company faces significant regulatory issues, including an FDA Warning Letter in December 2023 for manufacturing and distributing AXIOFILL™ without an approved biologics license and for significant deviations from current good manufacturing practice (CGMP) requirements, such as inadequate laboratory controls and insufficient in-process control procedures. The company's response to the FDA stated it does not agree that CGMP requirements are applicable to AXIOFILL™. In June 2019, 50 health complications were cited after MiMedx’s graft treatments, contradicting the company's claim of zero complications at the time. The company's Patient Assistance Program for uninsured patients requires household income below 250% of federal poverty guidelines, but no data on its reach or impact is provided. The company states it is committed to ethical clinical trials and posts them on ClinicalTrials.gov when required, with 5 of 12 low-risk-of-bias studies in a review being performed by MiMedx.

Fair Money & Economic Opportunity

MiMedx Group, Inc. is a biopharmaceutical company focused on developing and distributing placental tissue allografts for regenerative medicine. Its operations, as evidenced by the provided articles, involve healthcare products and services, such as distributing over 3 million allografts and managing payer coverage.

The company does not engage in financial services, lending, or banking activities, which are the focus of the 'Fair Money & Economic Opportunity' value. Therefore, all associated KPIs are not applicable to its business model.

Fair Pay & Worker Respect

In 2024, MiMedx Group's CEO to median employee pay ratio was 14:1, with the median employee earning $100,298.

Employee sentiment data from Glassdoor indicates an overall employee rating of 3.4 out of 5 stars based on 216 reviews, and 70% of employees would recommend working at the company. However, Indeed reviews show a lower overall rating of 2.6 out of 5 stars from 98 reviews. The company's voluntary employee turnover rate is reported to be high, at 40-50% annually. No specific data was provided for living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, insecure contract share, or health insurance coverage.

No War, No Weapons

MiMedx Group, Inc. received a $4.6 million award from the Department of Defense in May 2022 to advance the treatment of combat casualty wounds and burns using its PURION® processed Dehydrated Human Amnion Chorion Membrane (DHACM).

The company's Code of Business Conduct and Ethics emphasizes compliance with all applicable laws and regulations, including trade control regulations.

Zero Waste & Sustainable Products

The company has implemented several waste reduction initiatives, including a waste management program for medical and biohazardous waste, shredding and recycling of paper, transitioning to digital systems, and using electronic tablets for sales teams to minimize printing.

For hazardous waste, the company works with waste removal providers for responsible disposal, follows applicable packaging requirements for regulated medical waste, and provides regular training for employees. Products can be stored at room temperature for up to five years. A third-party environmental, health, and safety gap assessment has been conducted. The company has not reported any waste disposal violations in the past three years.